
Physician, educator, historian, author, podcaster, researcher @BIDMC_IM @HarvardMed @HarvardDBMI, host of @BedsideRounds, AE @NEJM_AI, studies 🤖+🧠. 🖖🚲
Boston, MA
Joined March 2010
- Tweets16.6K
- Following1.5K
- Followers18.3K
- Likes15.3K
Pinned Tweet
In case you were wondering why there hasn't been a new @BedsideRounds in a while ...
magazine.hms.harvard.edu/art…
Adam Rodman retweeted
We need a mindset shift in how we deploy AI. In the past, new capabilities unlocked new use cases. Safety, control, ethics, and skill erosion were important but usually secondary considerations; risks to be managed rather than gating criteria. But now and in the future, capability won't be the main bottleneck to deployment — considerations beyond productivity should be the decisive factor. The default question used to be "What can AI do?" But we need to start asking "Of the things AI can do, what should we actually delegate to it?"
Adam Rodman retweeted
Delaware’s northern border with Pennsylvania is one of the strangest state boundaries in America. Instead of following a river, mountain, or straight survey line, much of it is an arc of a circle.
The story of the circle's centre is wonderfully quirky...
1/n
Adam Rodman retweeted
Congrats to @BIDMChealth @AdamRodmanMD and team whose @Lancet study with @Google researchers is the first prospective real-world test of a patient-facing AI chatbot in primary care. Read more: nytimes.com/2026/10/08/techn…
Adam Rodman retweeted
Delighted to see our real-world clinical study of a conversational diagnostic AI system published in @TheLancet, alongside coverage in @nytimes last week.
Looking back, AI in medicine might feel inevitable but it actually takes deliberate, uncertain leaps to get there. I have been fortunate to be part of two such moments.
The first was early 2022 (pre ChatGPT) when @alan_karthi and I got access to our first @Google LaMDA and PaLM models. That convinced us to go all in on LLMs in medicine, sparking the Google Brain moonshot leading to Med-PaLM.
The second moment leading directly to this Lancet study, was late summer 2023.
@taotu831 showed me the early AMIE models he was training with our self-play loop, targeting our upcoming OSCE study with patient actors, later published in @Nature 2025.
At that exact time, I was navigating a personal health condition. Testing myself, the consultation the AI performed was so natural and clinically sound that I was convinced it was ready for the real world.
So I reached out to Alan and together with the team we asked how we could test this in the real world quickly, safely and responsibly. We needed a prospective clinical trial with a safety endpoint and all roads led to @AdamRodmanMD at @bethisraellahey @harvardmed .
Adam was incredibly gracious with his time kicking off our first discussions in the fall of 2023.
But clinical trials take a long time; years of painstaking work. There are so many critical people and moments that make them happen, far beyond the glitzy PR materials and the main authors.
- For example, a discussion with @greg_corrado sparked the design of the oversight setup underpinning the safety layer in the study.
- Kavita Kulkarni (now at BioHub) spent months negotiating the initial contracts with BIDMC; it was uncharted territory for both organizations.
- @_khaledsaab (now rocking at OpenAI!) working tirelessly to improve the AI, together with @taotu831, @apalepu13, @RyutaroTanno, @ckbjimmy, @valentinlievin, @elahevedadi and many more folks.
- @Mysiak, Alessio Orlandi, Petar Sirkovic and team sharing the seamless serving infrastructure they built for Co-Scientist, which we could re-use for much of this study.
- @SSaraMahdavi making sure the study team was well organized :)
This is just to name a few. Prospective trials are a massive team sport and I am proud of what our teams achieved.
While the AI's clinical reasoning was strong, seeing the patient trust, safety, and satisfaction data, with ZERO safety stops from our supervising physicians, is what truly stands out.
At the same time, this is still a stepping stone. We are moving from AI as a tool to an active care team member - a guardian angel amplifying clinicians and staying with patients throughout their health journey.
More to come soon, and as always, a pleasure to work with so many great folks across @GoogleDeepMind , @GoogleResearch and @bethisraellahey .
Paper - thelancet.com/journals/lance…
NYT - nytimes.com/2026/10/08/techn…
Three years ago @alan_karthi basically called me up out of the blue to ask how I would evaluate a patient-facing AI project that would become AMIE, which to my mind was a very strange thing to ask a nerdy physician-historian who is obsessed with ...
xitter.cf/AdamRodmanMD/status/21…
Our clinical trial of AMIE, a patient-facing AI system, was just published in The Lancet.
I want to explain what *I* think this study ACTUALLY means.
It's about a fundamental question: how do we know that clinical AI works?
🧵⬇️
xitter.cf/Google/status/21083245…
I know it's a ridiculous trope, but probably the best thing to come out of this study was the remarkable people I got to work with (and whom I *definitely* annoyed along the way).
Our clinical trial of AMIE, a patient-facing AI system, was just published in The Lancet.
I want to explain what *I* think this study ACTUALLY means.
It's about a fundamental question: how do we know that clinical AI works?
🧵⬇️
xitter.cf/Google/status/21083245…
Our medical research system, AMIE, is the first patient-facing conversational diagnostic tool of its kind to be studied prospectively in a real-world clinical setting.
In a study, published today in @TheLancet, we found that when patients chatted with AMIE before an in-person appointment, the interaction built their confidence and helped them organize their thoughts. And physicians who reviewed the information from the patient conversation got more time back to focus on collaborative care and shared decision-making instead of digging through data.
I'm enormously proud our work appeared in @TheLancet, even if it's just a phase I trial.
The bigger achievement is showing that patient-facing AI is ready to be studied in real clinical trials.
Next step: RCTs measuring patient outcomes, new workflows ...












